Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) FCF Margin (2016 - 2025)

Historic FCF Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 6127.12%.

  • Celldex Therapeutics' FCF Margin fell 49421400.0% to 6127.12% in Q2 2025 from the same period last year, while for Sep 2025 it was 6988.15%, marking a year-over-year decrease of 53876700.0%. This contributed to the annual value of 2275.2% for FY2024, which is 6900000.0% down from last year.
  • Per Celldex Therapeutics' latest filing, its FCF Margin stood at 6127.12% for Q2 2025, which was down 49421400.0% from 7865.47% recorded in Q1 2025.
  • Celldex Therapeutics' FCF Margin's 5-year high stood at 346.93% during Q2 2021, with a 5-year trough of 26270.51% in Q1 2024.
  • For the 5-year period, Celldex Therapeutics' FCF Margin averaged around 6574.54%, with its median value being 3734.54% (2021).
  • Per our database at Business Quant, Celldex Therapeutics' FCF Margin plummeted by -232556200bps in 2024 and then surged by 184050500bps in 2025.
  • Celldex Therapeutics' FCF Margin (Quarter) stood at 4454.19% in 2021, then skyrocketed by 69bps to 1363.73% in 2022, then surged by 41bps to 803.66% in 2023, then crashed by -252bps to 2830.13% in 2024, then plummeted by -116bps to 6127.12% in 2025.
  • Its last three reported values are 6127.12% in Q2 2025, 7865.47% for Q1 2025, and 2830.13% during Q4 2024.